|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Daiichi Sankyo Inc. |
|---|---|
| Information provided by: | Daiichi Sankyo Inc. |
| ClinicalTrials.gov Identifier: | NCT00185094 |
Purpose
To examine the effect of three different blood pressure medications on the insulin sensitivity in overweight patients with high blood pressure.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypertension Insulin Resistance Metabolic Syndrome |
Drug: Olmesartan medoxomil Drug: Losartan potassium Drug: Atenolol |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension |
| Estimated Enrollment: | 60 |
| Study Start Date: | February 2004 |
| Estimated Study Completion Date: | July 2005 |
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Alabama | |
| Birmingham, Alabama, United States | |
| United States, California | |
| San Diego, California, United States | |
| United States, Florida | |
| Miami, Florida, United States | |
| United States, Indiana | |
| Indianapolis, Indiana, United States | |
| United States, Maryland | |
| Baltimore, Maryland, United States | |
| United States, Massachusetts | |
| Boston, Massachusetts, United States | |
| United States, Minnesota | |
| Rochester, Minnesota, United States | |
| United States, Pennsylvania | |
| Philadelphia, Pennsylvania, United States | |
| United States, Texas | |
| Dallas, Texas, United States | |
| San Antonio, Texas, United States | |
More Information
| ClinicalTrials.gov Identifier: | NCT00185094 History of Changes |
| Other Study ID Numbers: | 866-440 |
| Study First Received: | September 9, 2005 |
| Last Updated: | December 22, 2005 |
| Health Authority: | United States: Food and Drug Administration |
|
Hypertension Insulin Resistance Overweight Metabolic Syndrome X Vascular Diseases Cardiovascular Diseases Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Body Weight Signs and Symptoms Atenolol Losartan Olmesartan medoxomil Olmesartan |
Anti-Arrhythmia Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Antihypertensive Agents Sympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |